Markets Demur as Trump Wields Tariffs
Stocks dropped Friday, a day after the S&P 500 posted a new record high, after President Donald Trump announced a 35% tariff on Canada and threatened higher tariffs across the board.The Dow Jones Industrials sank 339.77 points to begin Friday at 44,310.87.The S&P 500 lost 21.41 points to 6,259.05. The NASDAQ Composite dipped 8.39 points to 20,622.28.Friday’s losses pushed the major averages into the red for the week. Next week, investors will need to navigate the start of second-quarter earnings reporting season, along with the release of some key inflation data.Trump cited fentanyl as a reason for higher Canada duties, adding that they would go higher if the country retaliates. “If Canada works with me to stop the flow of Fentanyl, we will, perhaps, consider an adjustment to this letter,” Trump said in a letter posted on Truth Social.Trump then told NBC News he was planning blanket tariffs of 15% to 20% on remaining countries, higher than the current 10% standard that investors had grown comfortable with.JPMorgan led banks lower Friday, down about 1%. Citigroup lost about 1% as well, and Wells Fargo dipped 0.6%.Prices for the 10-year treasury fell, raising yields to 4.42% from Thursday’s 4.35%. Treasury prices and yields move in opposite directions. Oil prices improved $1.81 to $68.38 U.S. a barrel. Gold prices jumped $45.40 at $3,371.60 U.S. an ounce.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


